Extracted from this filing and checked against the source text.
Shareholder VotesSEC 8-K Item 5.07confidence 0.9
SANUWAVE Health, Inc. shareholders approved Approval of Agreement and Plan of Merger (Business Combination Proposal) at the 2024-02-21 meeting.
Proposal
merger approval
Outcome
passed
Meeting
2024-02-21
Exact text from the filing
Proposal 1 — To consider and vote upon a proposal to approve the Agreement and Plan of Merger (as it may be further amended or supplemented from time to time, the “Merger Agreement”) among the Company, SEP Acquisition Corp., a Delaware corporation (“SEPA”), and SEP Acquisition Holdings Inc., a Nevada corporation and a wholly-owned subsidiary of SEPA (“Merger Sub”), for the purposes set forth in the Merger Agreement (all of the transactions contemplated by the Merger Agreement, including the issuances of securities thereunder, are collectively referred to as the “Business Combination”), and the transactions contemplated thereby, including the Business Combination, pursuant to which Merger Sub will merge with and into the Company, with the Company continuing as the surviving entity of the Business Combination and becoming a subsidiary of SEPA (the “Business Combination Proposal”). For Against Abstain Broker Non-Votes 798,379,869 5,221,765 71,525 0
SANUWAVE Health, Inc. shareholders approved Adjournment proposal to permit further solicitation of proxies if necessary at the 2024-02-21 meeting.
Outcome
passed
Meeting
2024-02-21
Exact text from the filing
Proposal 2 — To adjourn the Special Meeting to a later date or dates, if necessary, to permit further solicitation and vote of proxies if it is determined by the Company’s board of directors that more time is necessary or appropriate to approve the Business Combination Proposal at the Special Meeting. For Against Abstain Broker Non-Votes 797,802,452 5,792,907 77,800 0
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.